

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT**Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page**

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP	
2. Address Address1 1800 CONCORD PIKE, P.O. BOX 15437 Address2 _____ City WILMINGTON State DE Zip Code 19850-5437 Country USA	
3. Principal place of business (if different than line 2) City _____ State _____ Zip Code _____ Country _____	
4a. Contact Name Ms. Jamie Bell	b. Telephone Number 2022467003
c. E-mail jamie.bell@astrazeneca.com	5. Senate ID# 54073-12
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP	6. House ID# 349750000

TYPE OF REPORT8. Year 2023 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31) 9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity **INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13**

<p align="center">12. Lobbying</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>830,000.00</u></p> <p>14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	---

Signature Digitally Signed By: Jamie BellDate 7/20/2023
7:10:12 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language), Medicare Part D reform, and inflation penalties.
 Issues related to the orphan drug exclusion of the Inflation Reduction Act.
 Issues related to clinical trial diversity.
 Issues related to lung cancer screening.
 Issues related to drug shortages.
 Issues related to workforce development.
 Issues related to the biopharmaceutical supply chain.
 Issues related to reauthorization of the Pandemics and All-Hazards Preparedness Act (PAHPRA).
 Issues related to rare disease patients with employer sponsored insurance.
 Issues related to Reform of pharmacy benefit managers.
 Issues related to the Cancer Moonshot Initiative.
 Issues related to Medicare reimbursement of patient navigators.
 Issues related to 340B.
 Issues related to drug shortages.
 Issues related to electronic prescribing labeling.
 FDA modernization policy issues.
 Reauthorization of newborn screening programs.
 General issues related to rare disease and orphan drugs.
 General issues related to health equity in rare disease and clinical trials.
 General issues related to diagnostics for patients with rare diseases.
 H.R. 1503, Prescription Information Modernization Act of 2023.
 H.R. 2407, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), White House Office, Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169).
 Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies.
 Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub. L. 117-169.
 CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure.
 Centers for Medicare and Medicaid Innovation (CMMI) policy issues.
 Issues pertaining to implementation of the Inflation Reduction Act, H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169).
 Medicare patient access to rare disease therapies, Part B and Part D drugs.
 Value-based payment arrangements.
 Efforts to improve coding, coverage, and access for rare disease therapies.
 General issues related to diagnostic reimbursement.
 S 2085, the Medicare Multi-Cancer Early Detection Screening Coverage Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to Pharmacy Benefit Managers (PBMs).
 Issues related to 340B reform.
 Issues related to prescription drug shortages.
 Issues related to the orphan drug exclusion of the Inflation Reduction Act.
 Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No. 117-169).
 S. 113, Prescription Pricing for the People Act of 2023.
 S. 127, Pharmacy Benefit Manager Transparency Act of 2023.
 S. 1038, Drug Price Transparency in Medicaid Act of 2023.
 H.R. 1613 Drug Pricing Transparency in Medicaid Act of 2023.
 H.R. 3561, PATIENT Act of 2023.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to the Orphan Drug Tax Credit.
 Issues related to the deduction of research and development expenditures.
 H.R. 1350, Camerons Law.
 H.R.2673, American Innovation and R&D Competitiveness Act of 2023.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

H.R. 4368, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024.
 H. Rept. 118-24, S. Rept. 118-44 -- Agriculture, Rural Development, and Food & Drug Administration appropriations; Issues related to the Labor, Health and Human Services, and Education appropriations.
 S. 2131, To provide for a limitation on availability of funds for Independent Agencies, National Historical Publications and Records Commission, Grants Program for fiscal year 2024.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Pharmaceutical IP and patent reform.
 S. 142, Preserve Access to Affordable Generics and Biosimilars Act.
 S. 150, Affordable Prescriptions for Patients Act of 2023.
 S. 1214, RARE Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code INS

16. Specific lobbying issues

Pharmacy Benefit Managers (PBM) reform.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

	First Name	Last Name	Suffix		First Name	Last Name	Suffix
1	Thad	Flood		3			
2				4			

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address	City	State/Province	Zip	Country	City
						State
						Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	City	State/Province			
				City		%
				State		
				Country		

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 2 3 4 5 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No Yes

Lobbyist Name	Description of Offense(s)